InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting

November 10, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2022 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2022 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.

InDex Pharmaceuticals conducts PK study with cobitolimod

August 19, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will conduct a clinical pharmacokinetic study (PK study) with cobitolimod in Sweden. The Swedish Medical Products Agency has given approval to start the study.

InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis

March 30, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2021 Annual General Meeting

December 3, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2021 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2021 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.

The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod

October 6, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint and cobitolimod demonstrated an outstanding combination of efficacy and safety.

InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences

August 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study will be presented orally at two leading gastroenterology conferences; the United European Gastroenterology Week (UEGW) and the American College of Gastroenterology (ACG) Annual Scientific Meeting. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint with an outstanding combination of efficacy and safety.

Update on InDex Pharmaceuticals Holding AB’s (InDex) Annual General Meeting addressing covid-19

April 8, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company plans to hold its Annual General Meeting 2020 as scheduled at 5.00 pm on April 20, 2020, but takes precautionary measures.

· Due to the risk for spread of infection InDex plans to limit the scope of the Annual General Meeting and the presence of the Board of Directors and Management.
· There will be no presentation by the CEO at the Annual General Meeting. InDex plans to provide update via other channels close to the Annual General Meeting.
· No food or refreshments will be served.
· The number of attendees will be limited in accordance with the restrictions in force at the time of the Annual General Meeting.

InDex Pharmaceuticals publishes mechanism of action data for cobitolimod in scientific journal

February 25, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC), shows that the Toll-like receptor 9 (TLR9) agonist cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. The publication has also been highlighted in the journal podcast.

InDex Pharmaceuticals presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019

November 18, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19. Both presentations will be livestreamed.

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2020 Annual General Meeting

November 1, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2020 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2020 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting

November 6, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2019 Annual General Meeting, which will be held on Monday May 6, 2019. The responsibility of the Nomination Committee is to present to the 2019 Annual General Meeting  proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.

InDex Pharmaceuticals publishes post-hoc analysis of the COLLECT study

October 19, 2018 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of a post-hoc analysis of COLLECT study data. COLLECT was a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod, a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC). The paper, published in the October issue of the peer-reviewed journal Digestive and Liver Disease (DLD), presents the clinical effect of cobitolimod on patient-reported outcomes (PRO) defined endpoints and in different patient subgroups defined by disease activity or anti-TNFα therapy exposure.

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee and financial reporting dates for 2018

November 16, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2018 Annual General Meeting, which will be held on Thursday May 24, 2018. The responsibility of the Nomination Committee is to present to the 2018 Annual General Meeting  proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditor.

InDex Pharmaceuticals will participate in the European Crohn’s and Colitis Organisation (ECCO) Congress

January 23, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will have two posters at the 12th congress of the European Crohn’s and Colitis Organisation (ECCO). The ECCO congress is the largest congress in the world with a specific focus on inflammatory bowel disease (IBD). The congress is held in Barcelona, Spain on February 15-18, 2017.

Results from InDex Pharmaceuticals’ COLLECT study well received at UEGW

October 18, 2016 – Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroenterology Week (UEGW) 2016 in Vienna.

InDex Pharmaceuticals presents results from the COLLECT study at the United European Gastroenterology Week 2016

October 10, 2016 – InDex Pharmaceuticals Holding AB (publ) announced today that results of additional analyses of data from COLLECT – a clinical study of its lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – will be presented orally and as a poster during the United European Gastroenterology Week (UEGW) October 15 – 19, 2016 in Vienna.

Trading in InDex Pharmaceutical’s shares starts October 11

October 6, 2016 – InDex Pharmaceuticals Holding AB (publ) has met the requirements for listing on Nasdaq First North Stockholm and the marketplace has now given its formal approval to the company. First day of trading in the share is Tuesday, October 11, 2016. The share will be traded under the ticker INDEX and with the ISIN code SE0008966295.

InDex Pharmaceuticals plans Initial Public Offering

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

August 19, 2016 – The Board of InDex Pharmaceuticals today announced its intention to proceed with an Initial Public Offering of the drug development company on Nasdaq First North during the autumn. A new share issue in order to raise capital for the development of the company’s lead drug candidate – cobitolimod – is planned in connection with the listing.

InDex Pharmaceuticals publishes results from COLLECT study

July 13, 2016 – InDex Pharmaceuticals AB today announced the publication of the results from COLLECT, a clinical study of the Toll-like receptor 9 (TLR9) agonist cobitolimod as a first-in-class treatment for patients with moderate to severe ulcerative colitis (UC). The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC), supports the potential of cobitolimod as a novel treatment for moderate to severe active ulcerative colitis.

InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct®

February 10, 2016 – InDex Pharmaceuticals AB today announced that the World Health Organization (WHO) has recommended cobitolimod as the International Nonproprietary Name (INN) for Index´s lead drug candidate Kappaproct®, which is a first-in-class Toll-like receptor (TLR) 9 agonist in late-stage clinical development for moderate to severe ulcerative colitis.

InDex Pharmaceuticals appoints Uli Hacksell and Jesper Wiklund to its Board of Directors

July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.

InDex Pharmaceuticals regains European rights to Kappaproct® in ulcerative colitis

June 30, 2015 – InDex Pharmaceuticals today announced the termination of a license agreement with Almirall S.A. relating to the drug candidate Kappaproct® for the treatment of ulcerative colitis. Under the agreement, which was signed in March 2014, Almirall licensed exclusive rights to Kappaproct® for the European market. Upon termination of the agreement, InDex regains all worldwide development and commercialization rights for Kappaproct®, which is in late-stage clinical development.

Peter Zerhouni new CEO of InDex Pharmaceuticals

February 5th, 2015 – InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.

InDex Pharmaceuticals to present results from the COLLECT trial at the 10th Congress of the European Crohn’s and Colitis Organisation

February 3rd, 2015 – InDex Pharmaceuticals today announced that results from COLLECT, a clinical study of the toll-like receptor 9 (TLR9) agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis, will be subject to an oral presentation at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). The congress is to be held in Barcelona, Spain on February 18-21, 2015.

InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct® in the treatment of moderate to severe Ulcerative Colitis

June 27, 2014 – InDex Pharmaceuticals today reported top-line results from the double blind, placebo-controlled clinical study COLLECT. The aim of the COLLECT study was to investigate the therapeutic potential of the Toll-like receptor 9 agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis.

Patients treated with Kappaproct showed statistically significant improvement on symptomatic remission (blood in stool, number of stools), registration remission (clinical remission with concurrent endoscopic remission) and the rate of colectomy. The rate of clinical remission (Rachmilewitz Index) was high in both the Kappaproct and the control group and no statistically significant difference was observed on this measure. Kappaproct was well tolerated and no safety signals compared to the standard of care treatment group were evident.

InDex Pharmaceuticals Expands Management Team

InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions…

Industrifonden new major shareholder in InDex Pharmaceuticals

Industrifonden invests MSEK 40 and becomes a new shareholder in InDex
Pharmaceuticals, which develops Kappaproct – a drug for treatment of severe
inflammatory bowel disease. Current shareholders, including SEB Venture Capital,
invest an additional MSEK 35. The financing will in large be used to conduct a clinical
phase III trial using Kappaproct with the aim of obtaining market approval.

InDex Pharmaceuticals Files Five More Patents

InDex Pharmaceuticals has filed five more patents that will further strengthen its
extensive portfolio of proprietary intellectual assets. “We have complemented our IP assets with some important…

Investor contact

Peter Zerhouni
Peter Zerhouni
+46 8 122 038 50